Niflumic acid

Revision as of 17:59, 10 April 2015 by Aparna Vuppala (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 457481224 | IUPAC_name = 2-{[3-(trifluoromethyl)phenyl]amino}nicotinic acid | image = Niflumic acid.png

| tradename = | Drugs.com = International Drug Names | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration =

| bioavailability = | protein_bound = | metabolism = | elimination_half-life = 2.5 hr[1] | excretion =

| CASNo_Ref =  ☒N | CAS_number_Ref =  ☑Y | CAS_number = 4394-00-7 | ATC_prefix = M01 | ATC_suffix = AX02 | ATC_supplemental = M02AA17 (WHO) | IUPHAR_ligand = 2439 | DrugBank_Ref =  ☑Y | DrugBank = | ChEMBL_Ref =  ☒N | ChEMBL = 63323 | UNII_Ref =  ☒N | UNII = 4U5MP5IUD8 | KEGG_Ref =  ☑Y | KEGG = D08275 | PubChem = 4488 | ChemSpiderID_Ref =  ☒N | ChemSpiderID = 4333 | smiles = C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F | InChI = 1/C13H9F3N2O2/c14-13(15,16)8-3-1-4-9(7-8)18-11-10(12(19)20)5-2-6-17-11/h1-7H,(H,17,18)(H,19,20) | InChIKey = JZFPYUNJRRFVQU-UHFFFAOYAR | StdInChI_Ref =  ☒N | StdInChI = 1S/C13H9F3N2O2/c14-13(15,16)8-3-1-4-9(7-8)18-11-10(12(19)20)5-2-6-17-11/h1-7H,(H,17,18)(H,19,20) | StdInChIKey_Ref =  ☒N | StdInChIKey = JZFPYUNJRRFVQU-UHFFFAOYSA-N

| C=13 | H=9 | F=3 | N=2 | O=2 | molecular_weight = 282.21797 g/mol }}


WikiDoc Resources for Niflumic acid

Articles

Most recent articles on Niflumic acid

Most cited articles on Niflumic acid

Review articles on Niflumic acid

Articles on Niflumic acid in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Niflumic acid

Images of Niflumic acid

Photos of Niflumic acid

Podcasts & MP3s on Niflumic acid

Videos on Niflumic acid

Evidence Based Medicine

Cochrane Collaboration on Niflumic acid

Bandolier on Niflumic acid

TRIP on Niflumic acid

Clinical Trials

Ongoing Trials on Niflumic acid at Clinical Trials.gov

Trial results on Niflumic acid

Clinical Trials on Niflumic acid at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Niflumic acid

NICE Guidance on Niflumic acid

NHS PRODIGY Guidance

FDA on Niflumic acid

CDC on Niflumic acid

Books

Books on Niflumic acid

News

Niflumic acid in the news

Be alerted to news on Niflumic acid

News trends on Niflumic acid

Commentary

Blogs on Niflumic acid

Definitions

Definitions of Niflumic acid

Patient Resources / Community

Patient resources on Niflumic acid

Discussion groups on Niflumic acid

Patient Handouts on Niflumic acid

Directions to Hospitals Treating Niflumic acid

Risk calculators and risk factors for Niflumic acid

Healthcare Provider Resources

Symptoms of Niflumic acid

Causes & Risk Factors for Niflumic acid

Diagnostic studies for Niflumic acid

Treatment of Niflumic acid

Continuing Medical Education (CME)

CME Programs on Niflumic acid

International

Niflumic acid en Espanol

Niflumic acid en Francais

Business

Niflumic acid in the Marketplace

Patents on Niflumic acid

Experimental / Informatics

List of terms related to Niflumic acid

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Niflumic acid is a drug used for joint and muscular pain. It is categorized as an inhibitor of cyclooxygenase-2. In experimental biology, it has been employed to inhibit chloride channels.[2] It has also been reported to act on GABA-A[3] and NMDA channels[4] and to block T-type calcium channels.[5]

References

  1. "Half life". Drug Bank. Retrieved 15 July 2011.
  2. Knauf, Philip A.; Mann, Nancy A (1984). "Use of niflumic acid to determine the nature of the asymmetry of the human erythrocyte anion exchange system". J. Gen. Physiol. 83: 703–725. doi:10.1085/jgp.83.5.703. PMC 2215658. PMID 6736917.
  3. Sinkkonen ST et al. (2003): Receptor subtype-dependent positive and negative modulation of GABA(A) receptor function by niflumic acid, a nonsteroidal anti-inflammatory drug, Mol Pharmacol, p. 753-63. PMID 12920213
  4. Lerma J., Martin d.R. (1992). "Chloride transport blockers prevent N-methyl-D-aspartate receptor-channel complex activation". Mol. Pharmacol. 41 (2): 217–222. PMID 1371581.
  5. Balderas E et al. (2012): Niflumic acid blocks native and recombinant T-type channels, J Cell Physiol, p. 2542-55. PMID 21898399

Template:Topical products for joint and muscular pain

Template:GABAAR PAMs